OUR FOUNDING TEAM
Dr. Brian Courtney and Dr. Aman Thind came together in 2007 to build the foundation for a medical device company.
Brian and Aman found out very early in their partnership that they could work well together and complemented each other’s abilities.
They were good at identifying solutions to complex problems with true clinical impact. Brian and Aman also realized the importance of partnerships clinically, academically as well as with government and industry. With this, they decided to build a company together that would build on these partnerships and allow for development of critically important medical devices in Canada.
Novasight Hybrid System Receives FDA 510(k) Clearance
Conavi receives 510(k) clearance from the US Food and Drug Administration (FDA) for our Novasight Hybrid System. The system enables simultaneous imaging of coronary arteries with both intravascular ultrasound (IVUS) and Optical Coherence Tomography (OCT). IVUS or OCT are typically used by interventional cardiologists to image coronary anatomy during angioplasty and stenting procedures.
Dr. Courtney continues, “This regulatory clearance represents an important milestone for the company as we build a portfolio of image guidance products for cardiovascular procedures. We are delighted to now be able to offer physicians in the USA the opportunity to use the Novasight Hybrid System to obtain intravascular images of coronary arteries as part of their care for patients undergoing interventional procedures.”
Conavi Enters into Distribution Agreement with China Grand Pharmaceutical and Healthcare
Conavi announces that we have entered into an agreement with an affiliate of China Grand Pharmaceutical and Healthcare Holdings Limited (CG Healthcare) to serve as the exclusive distributor of our Foresight ICE System and Novasight Hybrid System in China, Hong Kong, Taiwan and Macau.
Conavi’s Foresight ICE System has received 510(k) clearances from the United States Food & Drug Administration (FDA) and a Medical Device License from Health Canada and is currently being marketed in North America. The Novasight Hybrid System combines the two most frequently used intravascular imaging technologies, intravascular ultrasound (IVUS) and optical coherence tomography (OCT), into a single catheter and platform. The Novasight Hybrid System has been submitted to the US FDA for 510(k) clearance.
Foresight ICE™ System Receives FDA Clearance for Expanded Feature Set
Conavi announces 510(k) clearance from the FDA for our Foresight ICE System expanded feature set. The enhancements include Color Doppler, Pulsed Wave Doppler, 2D and 3D measurements, and ECG-gated 3D image acquisition. These enhancements are expected to help electrophysiologists and interventional cardiologists in the US by providing them with the tools to make decisions during minimally invasive cardiovascular procedures.
“This system is the world’s first intracardiac echo system with the capability to acquire 2D and 3D images with a broad field-of-view that includes both side-viewing and forward-looking capabilities. We have now expanded upon this foundation by adding image quality enhancements, features to minimize the effects of cardiac motion and the inclusion of additional imaging modes.” says Dr. Brian Courtney, CEO of Conavi.
The system’s indication for use has been expanded to include the ability to assess physiology with its new Doppler capabilities. Dr. Courtney continues, “The addition of Doppler imaging and flow quantification greatly expands the range of clinical scenarios in which Conavi’s Foresight ICE System can be used. As a result, we are the only provider of rotational ICE that provides Doppler capabilities, and thus benefit from being able to target regions of the cardiac anatomy anywhere around the 360-degree field-of-view of our catheter. The achievement of this 510(k) clearance demonstrates Conavi’s commitment to being a highly responsive source of imaging technologies to physicians performing electrophysiology procedures, structural heart interventions and other cardiovascular procedures that stand to benefit from image guidance.”
Conavi Partners with Nova Scotia Health Authority and Government of Canada
Conavi announces that we are spearheading a collaborative effort to develop an imaging and tissue cutting probe for guided cardiovascular surgeries. The miniaturized probe leverages ultrasound technology for both imaging and precision cutting, allowing physicians to diagnose and treat serious conditions in a minimally invasive manner.
The Government of Canada is investing $2.6+ million over five years in the Nova Scotia Health Authority (NSHA) to develop the endoscope prototype. Throughout the development, Conavi will lend our medical and technological expertise to assist the NSHA in taking the solution from concept to creation. Upon creation, Conavi will commercialize the solution for cardiovascular surgical applications, allowing patients worldwide to benefit from improved clinical outcomes.
Fellow Toronto-based company Synaptive Medical will also assist in developing the solution and will likewise commercialize the solution for neurological applications.
Conavi Medical announces Health Canada clearance
Conavi announces that we are now authorized to market and sell the Foresight ICE™ System in Canada. The Foresight ICE System is the first catheter-based ultrasound system capable of providing both 2D and 3D ultrasound images of cardiac anatomy around the circumference of the catheter’s tip.
The authorization comes from Health Canada—Canada’s federal regulator responsible for monitoring and evaluating the safety, effectiveness, and quality of diagnostic and therapeutic medical devices. After evaluating the Foresight ICE System, Health Canada granted a Canadian Medical Device License (MDL)—giving us the clearance needed to market the solution in our home country of Canada.
“Attaining Health Canada approval for our Foresight ICE System represents a key milestone in our mission to provide Canadian physicians with superior visual guidance to achieve improved clinical outcomes” says Murray Maynard, President and CEO of Conavi Medical. “Not only does this approval allow us to begin marketing our technology in Canada, but a device license in our domestic market is key to obtaining regulatory approval in other jurisdictions.”
Early results from Southlake Regional Health Centre Study
Southlake Regional Health Centre is supporting the first phase of the Foresight ICE Trial using technology initially developed at Sunnybrook Research Institute. This study is looking at the first clinical use and efficacy of 2D forward and 3D intracardiac echocardiography to guide trans-septal punctures during AF ablation procedures. Several patients have already had successful trans-septal puncture supported by the use of the Foresight ICE system.
Foresight ICE System Receives FDA 510(k) clearance
Conavi Medical (formerly Colibri Technologies) announces FDA 510(k) clearance for its first product, the Foresight ICE System for Intracardiac Echocardiography.
The Foresight ICE System is the first catheter- based ultrasound system capable of providing both 2D and 3D ultrasound images of cardiac anatomy around the circumference of the catheter’s tip. The system includes the dual display Conavi Hummingbird imaging console and the Foresight ICE catheter. These products can be used to support a growing number of minimally invasive cardiovascular procedures performed in the US, such as ablations and other procedures that may require access to targeted regions of the heart.
Conavi partners with OBIO
The Ontario Bioscience Innovation Organization (OBIO) is a not-for-profit, membership-based organization engaged in the development of an integrated health innovation economy for Ontario and one that will become a global leader in providing health technology products and services to the international marketplace.
OBIO’s priorities are to build companies that can stay here and grow and a sustainable industry that will: strengthen Ontario’s economy; commercialize research output; employ the best-educated, most innovative workers in the world and provide cost effective, value-driven healthcare solutions. Conavi Medical was selected as a Capital Access Advisory Program (CAAP) Company in which OBIO operates downstream from existing entrepreneurship programs and targets the critical issue of access to capital at the “Series A” and later stages of venture financing. Led by OBIO and a North American Steering Committee of life science venture capitalists and serial entrepreneurs, CAAP Companies work closely with a team of CAAP Advisors to address specific goals and objectives to position them for financing success. In addition to investor materials preparation and guidance, CAAP Goals include intellectual property, clinical and regulatory, market access other key strategic items to position companies for financing success
Japan Lifeline and Conavi enter partnership
Conavi and Japan Lifeline (JLL) have signed an agreement to allow JLL to serve as the exclusive distributor of Conavi’s intracardiac echocardiography imaging system in Japan. The companies are working together to obtain the necessary regulatory and reimbursement approval.
Download our Press Release.
Conavi becomes a proud partner of HTX
From Invention through Innovation to International Invoice, HTX provides non-dilutive project financing to emerging and established Ontario-based companies to develop, produce and commercialize innovative market-leading advanced health technologies. Through its Health Technology Commercialization Program (HTCP), its new REACH Innovation Procurement program, and its MedTech ecosystem support activities, HTX is the leading resource and catalyst for accelerating the growth of Ontario’s MedTech industry. The work supported by this partnership has been supported through financing provided by the Health Technology Commercialization Program through htx.ca – The Health Technology Exchange (HTX) and with the support of Sunnybrook Research Institute. This Program has also been made available through the support of the Ontario Ministry of Research and Innovation (MRI).
Conavi is Built on Leadership
Dr. Brian Courtney
Dr. Aman Thind
Conavi is Built on Leadership
Stefano E. Picone, CPA/CA
Marc Lukacs, PhD
Chris Jerger, MSEE, P.Eng
Morteza Aval, P. Eng
Director, Quality & Regulatory
Board of Directors
President, Synaptive Medical
President, Baylis Medical
Partner, CPOINT Capital
President, Area One Farms
CEO, Bridgebank Capital
Michael K. Wang
Vice President, Grandpharma (China) Co., Ltd.